Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

How to design effective vaccines: lessons from an old success story.

Ahmed N, Gottschalk S.

Expert Rev Vaccines. 2009 May;8(5):543-6. doi: 10.1586/erv.09.26. Review.

PMID:
19397411
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Systems biology in vaccine design.

Six A, Bellier B, Thomas-Vaslin V, Klatzmann D.

Microb Biotechnol. 2012 Mar;5(2):295-304. doi: 10.1111/j.1751-7915.2011.00321.x. Epub 2011 Dec 21. Review.

PMID:
22189033
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

Barrett AD, Teuwen DE.

Curr Opin Immunol. 2009 Jun;21(3):308-13. doi: 10.1016/j.coi.2009.05.018. Epub 2009 Jun 10. Review.

PMID:
19520559
[PubMed - indexed for MEDLINE]
4.

Acute viscerotropic disease following vaccination against yellow fever.

Hayes EB.

Trans R Soc Trop Med Hyg. 2007 Oct;101(10):967-71. Epub 2007 Jul 31. Review.

PMID:
17669451
[PubMed - indexed for MEDLINE]
5.

Yellow fever vaccine: past, present and future.

Roukens AH, Visser LG.

Expert Opin Biol Ther. 2008 Nov;8(11):1787-95. doi: 10.1517/14712598.8.11.1787 . Review.

PMID:
18847312
[PubMed - indexed for MEDLINE]
6.

Review of the risks and benefits of yellow fever vaccination including some new analyses.

Monath TP.

Expert Rev Vaccines. 2012 Apr;11(4):427-48. doi: 10.1586/erv.12.6. Review.

PMID:
22551029
[PubMed - indexed for MEDLINE]
7.

Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D.

Querec TD, Pulendran B.

Adv Exp Med Biol. 2007;590:43-53. Review. No abstract available.

PMID:
17191376
[PubMed - indexed for MEDLINE]
8.

Yellow fever vaccines and international travelers.

Barnett ED, Wilder-Smith A, Wilson ME.

Expert Rev Vaccines. 2008 Jul;7(5):579-87. doi: 10.1586/14760584.7.5.579. Review.

PMID:
18564013
[PubMed - indexed for MEDLINE]
9.

Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine.

Zuckermann FA, Martin S, Husmann RJ, Brandt J.

Adv Vet Med. 1999;41:447-61. Review.

PMID:
9890035
[PubMed - indexed for MEDLINE]
10.

New developments in flavivirus vaccines with special attention to yellow fever.

Pugachev KV, Guirakhoo F, Monath TP.

Curr Opin Infect Dis. 2005 Oct;18(5):387-94. Review.

PMID:
16148524
[PubMed - indexed for MEDLINE]
11.

Safety of 17D derived yellow fever vaccines.

Domingo C, Niedrig M.

Expert Opin Drug Saf. 2009 Mar;8(2):211-21. doi: 10.1517/14740330902808086 . Review.

PMID:
19309249
[PubMed - indexed for MEDLINE]
12.

Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.

Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T.

Vaccine. 2011 Jun 20;29(28):4544-55. doi: 10.1016/j.vaccine.2011.04.055. Epub 2011 May 5. Review.

PMID:
21549787
[PubMed - indexed for MEDLINE]
13.

[Yellow fever].

Wiercińska-Drapało A.

Przegl Epidemiol. 2004;58 Suppl 1:101-5. Review. Polish.

PMID:
15807166
[PubMed - indexed for MEDLINE]
14.

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J.

Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13. Review.

PMID:
21745521
[PubMed - indexed for MEDLINE]
15.

Yellow fever: the recurring plague.

Tomori O.

Crit Rev Clin Lab Sci. 2004;41(4):391-427. Review.

PMID:
15487593
[PubMed - indexed for MEDLINE]
16.

Yellow fever: epidemiology and prevention.

Barnett ED.

Clin Infect Dis. 2007 Mar 15;44(6):850-6. Epub 2007 Feb 1. Review.

PMID:
17304460
[PubMed - indexed for MEDLINE]
Free Article
17.

Is it time for a new yellow fever vaccine?

Hayes EB.

Vaccine. 2010 Nov 29;28(51):8073-6. doi: 10.1016/j.vaccine.2010.10.015. Epub 2010 Nov 3. Review.

PMID:
20971115
[PubMed - indexed for MEDLINE]
18.

Yellow fever-associated viscerotropic disease in Barcelona, Spain.

Muñoz J, Vilella A, Domingo C, Nicolas JM, de Ory F, Corachan M, Tenorio A, Gascon J.

J Travel Med. 2008 May-Jun;15(3):202-5. doi: 10.1111/j.1708-8305.2008.00209.x. Review.

PMID:
18494699
[PubMed - indexed for MEDLINE]
19.

Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged.

Tang YC, Thoman M, Linton PJ, Deisseroth A.

Cancer Immunol Immunother. 2009 Dec;58(12):1949-57. doi: 10.1007/s00262-009-0718-3. Epub 2009 May 15. Review.

PMID:
19444444
[PubMed - indexed for MEDLINE]
20.

Yellow fever vaccine safety: a reality or a myth?

Arya SC.

Vaccine. 2002 Nov 1;20(31-32):3627-8. Review.

PMID:
12399186
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk